High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock — HICOSS

Systemic Inflammatory Response Syndrome Clinical Trial

Official title:
High Cut-off Continuous Venovenous Hemodialysis (CVVHD) to Improve Hemodynamic Stability and Organ Function Scores in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock

Status Terminated

Clinical Trial Summary

This study will assess the influence of the High Cut-Off (HCO) CVVHD treatment on the disease progression in septic patients. The primary aim of the study is to evaluate whether HCO CVVHD leads to a significant improvement of the hemodynamic status (mean arterial pressure, vasopressor requirements) in septic patients in comparison to CVVHD treatment with conventional high-flux filters. For the HCO-group the investigators expect a 50% lower dosage of vasopressors needed to maintain an adequate organ perfusion.

Clinical Trial Description

Severe sepsis is a devastating disorder that results from a complex host response to insult after infection. Despite advances in intensive care technologies sepsis remains an important and life-threatening problem. Sepsis is the most common cause of death in the intensive care unit.

Local or systemic release of bacteria-derived compounds, leading to the production of proinflammatory cytokines, induce systemic inflammatory reactions in septic patients. Continuous renal replacement therapies (CRRT) such as hemodialysis (CVVHD), hemofiltration (CVVH) or hemodiafiltration (CVVHDF) with conventional high-flux membranes allow to control fluid and electrolyte balance, and to improve the hemodynamic status of the patients. However, conventional high flux membranes have a limited permeability for sepsis-associated mediators with molecular weights in the range of 15.000 to 60.000 Da.

A promising approach to enhance the mediator removal is to use membranes having larger pores and permeability characteristics than those currently used in CRRT.

For that purpose a High Cut-Off (HCO) membrane has been developed and is manufactured by Gambro Research.After demonstrating the safety as well as the cytokine removal effectiveness in a clinical pilot study this study will assess the influence of the HCO treatment on the disease progression in septic patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00875888
Study type	Interventional
Source	Baxter Healthcare Corporation
Contact
Status	Terminated
Phase	N/A
Start date	February 2004
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02518087` - Increased Adsorption Membranes During Cardiopulmonary Bypass	N/A
Completed	`NCT02902939` - Myeloid-Derived Supressor Cells in Cardiac Surgery Patients	N/A
Completed	`NCT02563652` - Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?
Recruiting	`NCT01157299` - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO	N/A
Completed	`NCT01388725` - Comparison the Value of Several Biomarkers of Sepsis	N/A
Unknown status	`NCT00254176` - Cysteine Supplementation in Critically Ill Neonates	Phase 2/Phase 3
Not yet recruiting	`NCT03617796` - Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
Completed	`NCT03876041` - Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome	Phase 4
Recruiting	`NCT05608096` - European Registry for Hemadsorption in Sepsis With the Seraph Filter
Completed	`NCT03314831` - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed	`NCT02568410` - Platelets as Regulators of Inflammation in Cardiac Surgery
Completed	`NCT01636232` - Vitamin D and Critically Ill Patients	N/A
Completed	`NCT01020409` - INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery	Phase 4
Completed	`NCT04624776` - Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest	Phase 2
Recruiting	`NCT05172739` - Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC	Phase 4
Recruiting	`NCT02957175` - Immunophenotyping of Patients With Postoperative SIRS
Completed	`NCT02320539` - MicroRNA Diagnostics in Subarachnoid Hemorrhage 2	N/A
Completed	`NCT01708759` - IL8 Monitoring and Its Correlation With 251-gene Polymorphism	N/A
Terminated	`NCT00708799` - Efficacy of Macrolide Immunomodulation in Severe Sepsis.	Phase 2
Recruiting	`NCT04580680` - Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.